宏源药业
(301246)
| 流通市值：30.24亿 | | | 总市值：70.00亿 |
| 流通股本：1.73亿 | | | 总股本：4.00亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 1,341,942,986.85 | 703,525,713.02 | 1,939,468,837.26 | 1,317,076,113.48 |
| 营业总成本 | 1,156,301,588.45 | 543,865,867.35 | 1,794,917,960.56 | 1,292,835,287.81 |
| 其他经营收益 | | | | |
| 营业利润 | 221,826,286.16 | 183,627,386.63 | 158,267,273.66 | 6,603,683.47 |
| 利润总额 | 203,073,513.37 | 164,865,777.42 | 145,715,190.34 | 5,196,279.4 |
| 净利润 | 155,490,305.32 | 144,197,566.58 | 117,629,722.13 | -1,943,993.04 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | 155,490,305.32 | 144,197,566.58 | 117,629,722.13 | -1,943,993.04 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 3,327,623,204.35 | 3,340,600,138.23 | 3,296,902,250.34 | 3,138,678,439.75 |
| 非流动资产: | | | | |
| 非流动资产合计 | 3,081,974,704.71 | 2,942,782,742.73 | 2,867,710,580.21 | 2,763,078,666.92 |
| 资产总计 | 6,409,597,909.06 | 6,283,382,880.96 | 6,164,612,830.55 | 5,901,757,106.67 |
| 流动负债: | | | | |
| 流动负债合计 | 1,263,865,304.75 | 1,158,166,565.89 | 1,241,213,008.41 | 1,077,617,549.01 |
| 非流动负债: | | | | |
| 非流动负债合计 | 542,457,515.2 | 517,635,919.94 | 464,573,085.24 | 488,273,074.96 |
| 负债合计 | 1,806,322,819.95 | 1,675,802,485.83 | 1,705,786,093.65 | 1,565,890,623.97 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 4,604,751,211.85 | 4,608,458,628.95 | 4,459,554,952.22 | 4,335,419,133.28 |
| 股东权益合计 | 4,603,275,089.11 | 4,607,580,395.13 | 4,458,826,736.9 | 4,335,866,482.7 |
| 负债和股东权益合计 | 6,409,597,909.06 | 6,283,382,880.96 | 6,164,612,830.55 | 5,901,757,106.67 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 913,025,529.3 | 269,357,413.63 | 1,119,623,900.72 | 845,673,148.96 |
| 经营活动现金流出小计 | 873,508,748.9 | 279,848,926.51 | 1,304,585,926.86 | 1,031,063,070.06 |
| 经营活动产生的现金流量净额 | 39,516,780.4 | -10,491,512.88 | -184,962,026.14 | -185,389,921.1 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,801,068,647.94 | 432,374,202.49 | 5,389,464,409.32 | 4,186,480,447.33 |
| 投资活动现金流出小计 | 2,040,170,044.02 | 631,000,870.27 | 5,630,093,034.64 | 4,828,292,020.47 |
| 投资活动产生的现金流量净额 | -239,101,396.08 | -198,626,667.78 | -240,628,625.32 | -641,811,573.14 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 220,641,422.49 | 81,750,657.99 | 583,099,426.01 | 508,037,678.01 |
| 筹资活动现金流出小计 | 213,729,536.34 | 71,047,426.36 | 351,752,085.3 | 171,933,170.45 |
| 筹资活动产生的现金流量净额 | 6,911,886.15 | 10,703,231.63 | 231,347,340.71 | 336,104,507.56 |
| 汇率变动对现金及现金等价物的影响 | -2,365,081.33 | -1,500,551.33 | -354,941.99 | 581,007.55 |
| 现金及现金等价物净增加额 | -195,037,810.86 | -199,915,500.36 | -194,598,252.74 | -490,515,979.13 |
| 期末现金及现金等价物余额 | 192,550,314.42 | 187,672,624.92 | 387,588,125.28 | 91,670,398.89 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -195,037,810.86 | - | -194,598,252.74 | - |